Nanostasis intravenous agent for traumatic hemorrhage control
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110463
- Recipient
-
Cayuga Biotech Inc. UEI HXQXY36J3156
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $922,870
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Basking Ridge, Bernards, NJ, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded Cayuga Biotech Inc. a $922,870 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support Cayuga Biotech's development of an intravenous agent for traumatic hemorrhage control from July 1, 2021 to June 30, 2022. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions, including investigations into battlefield medicine. Under this award, Cayuga Biotech will develop an intravenous therapeutic agent to control hemorrhaging, a key medical challenge for both military combat casualties and civilian trauma patients. The work will be conducted at Cayuga Biotech's facility located in Basking Ridge, New Jersey.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $922,870 |
Quick answers
Who received award W81XWH2110463?
W81XWH2110463 was awarded to Cayuga Biotech Inc. by Medical Command (Department of the Army) on July 1, 2021.
How much is award W81XWH2110463 worth?
$922,870 has been obligated on W81XWH2110463.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award